Full-Time

Quality Specialist

Posted on 9/9/2026

Nucleus Biologics

Nucleus Biologics

51-200 employees

Cell culture media and supplements provider

Compensation Overview

$70k - $80k/yr

San Diego, CA, USA

In Person

Occasional travel between Nucleus Biologics facilities may be required.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
GMP
Quality Assurance (QA)

Get referred to Nucleus Biologics

See people who can refer or advise you

Requirements
  • A high school diploma is required; a bachelor's degree in a scientific discipline, engineering, quality assurance, or a related field is preferred, and a combination of education and experience will be considered.
  • Two to four years of experience in quality assurance and/or document control within a cGMP pharmaceutical, biotechnology, or medical device environment.
  • Working knowledge of Good Manufacturing Practices, International Organization for Standardization requirements, and United States Food and Drug Administration regulatory requirements.
  • Experience with electronic quality management systems is required; hands-on experience with ZenQMS is highly desired.
  • Ability to communicate effectively both orally and in writing and establish and maintain productive working relationships.
  • Ability to work effectively in a fast-paced environment, prioritize tasks, and manage multiple assignments simultaneously.
  • Ability to exercise independent judgment consistent with company guidelines.
  • Ability to hear and speak to employees and external associates by phone and in person.
  • Ability to see letters and numbers on a personal computer screen and on memos, reports, and other documents using near vision.
  • Ability to walk and/or drive between buildings on campus, up to 0.3 miles for San Diego-based positions.
Responsibilities
  • Support the document control system, including the creation, review, approval, distribution, and archival of controlled documents and quality records.
  • Control the distribution of current document revisions to prevent use of obsolete documents and maintain document retention practices in accordance with company policy and regulatory requirements.
  • Execute record archival activities in accordance with company policy and regulatory requirements.
  • Issue manufacturing records and associated labeling to support upcoming production needs.
  • Issue batch records, logs, and other quality records to support production, testing, and release activities.
  • Assign and track training on new and revised controlled documents.
  • Serve as Change Request Coordinator by overseeing the creation, editing, and revision of controlled documentation through the change request process.
  • Review batch records, logs, manufacturing documentation, and associated data for accuracy, completeness, and compliance with established procedures.
  • Issue part numbers and validation protocol or document numbers as needed to support quality, production, and validation activities.
  • Support raw material and finished goods release activities.
  • Provide support during internal audits, customer audits, and regulatory inspections, including audit readiness activities.
  • Retrieve and compile documents and records requested during audits and inspections.
  • Enter and maintain quality data in the electronic quality management system.
  • Generate routine reports and key performance indicators, including document turnaround time, overdue approvals, training compliance, and record status.
  • Identify trends and opportunities for process improvement within document control and quality assurance activities.
Desired Qualifications
  • A bachelor's degree in a scientific discipline, engineering, quality assurance, or a related field.
  • Hands-on experience with ZenQMS.
  • Occasional travel between Nucleus Biologics facilities.

Nucleus Biologics is a biotechnology supplier that provides media and supplements for the cell and gene therapy space. It offers precision cell culture products and tools, manufactured under cGMP standards, to support researchers and clinicians globally. Their products are designed to improve reproducibility in cell culture and enable faster progress from scientific discovery to cures, while delivering transparent information and services. The company differentiates itself by emphasizing reproducibility, clear cGMP-compliant materials, and a willingness to disrupt traditional, outdated practices with a broader environmental focus. The goal is to create a new paradigm that benefits scientists and clinicians, speeds therapy development, and reduces the environmental footprint of cell culture.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

San Diego, California

Founded

2016

Get referred to Nucleus Biologics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 5, 2026 CRAIC Formulation Finder broadens NB-Lux adoption among scientists.
  • May 12, 2026 NB-Lux claims faster R&D-to-GMP cycles and real-time order visibility.
  • February 10, 2026 K500 targets lower costs, easier scale-up, and cleaner manufacturing footprints.

What critics are saying

  • GMP software and automation face long validation cycles; a single failure delays revenue.
  • K500 sold only two units in February 2026, signaling weak early traction.
  • If K500 and NB-Lux fail GMP qualification, Nucleus becomes a niche services vendor.

What makes Nucleus Biologics unique

  • May 12, 2026 NB-Lux AI fuses formulation, quoting, manufacturing, and document control.
  • February 10, 2026 Krakatoa K500 makes 35–500L media at point-of-use in under three hours.
  • January 9, 2025 EXCiPACT plus ISO 9001 certify excipient GMP operations.

Help us improve and share your feedback! Did you find this helpful?

Company News

Associated Press
Jul 7th, 2026
Nucleus Biologics launches CRAIC AI assistant for cell culture media development

Nucleus Biologics has launched CRAIC™ Formulation Finder, a large language model assistant for cell culture media and buffer development. The tool allows scientists to describe desired biological outcomes in natural language, and CRAIC™ generates tailored formulation recommendations within minutes based on cell type, phenotype, and manufacturing considerations. The AI assistant integrates with Nucleus Biologics' NB-Lux™ AI platform, enabling users to move directly from formulation discovery to customisation, quoting, and ordering. The system combines LLMs with the company's formulation expertise and manufacturing database, allowing researchers to develop and test optimised formulations within 30 days. "Scientists can now own an optimised media leveraging the human atlas of scientific research," said David Sheehan, founder and CEO. CRAIC™ is currently available within the NB-Lux™ AI platform.

Business Wire
May 12th, 2026
Nucleus Biologics launches NB-Lux AI ecosystem to cut GMP media production time to 4 weeks

Nucleus Biologics has launched NB-Lux AI, an AI-enabled digital ecosystem for media and buffer manufacturing in advanced therapies. The platform integrates formulation design, feasibility analysis, ordering, manufacturing and documentation into a single continuous workflow, reducing GMP media delivery time to four weeks. Building on the company's 2020 cloud-based ordering portal, NB-Lux AI features AI-driven feasibility analysis, automated quoting, real-time order tracking and a secure document repository called "the Vault" for regulatory filings. The system eliminates manual processes by digitising the entire workflow from formula to GMP release. The platform enables therapy developers to customise formulations whilst maintaining complete ownership and visibility. It integrates directly with Krakatoa manufacturing systems and supports seamless scaling from R&D to Excipient GMP manufacturing.

Business Wire
Feb 10th, 2026
Nucleus Biologics launches Krakatoa K500 pod-based system for on-demand media and buffer production

Nucleus Biologics has launched the Krakatoa K500, a pod-based media and buffer manufacturing system for bioreactor-scale production. The system produces up to 500 litres of sterile solutions in under three hours with less than 15 minutes of hands-on time. The automated system uses preformulated powder-filled pods and a closed single-use workflow to eliminate cold-chain transport, refrigerated storage and centralised media preparation. It features QR-code-driven operation, continuous inline monitoring and automated digital batch record generation for GMP compliance. The San Diego-based company developed the product over six years to reduce costs and complexity in advanced therapy development. Founder David Sheehan said the system aims to create a new paradigm for delivering bioprocessing liquids to bioreactors whilst improving patient access through cost reduction.

San Diego Biotechnology Network
Feb 10th, 2026
Nucleus Biologics Launches Krakatoa(R) K500: A Pod-Based, On-Demand Media and Buffer Manufacturing System Transforming Scale Bioproduction

Nucleus Biologics launches Krakatoa(R) K500: A pod-based, on-demand media and buffer manufacturing system transforming scale bioproduction. February 10, 2026 SDBN news, syndication comments off on Nucleus Biologics launches Krakatoa(R) K500: A pod-based, on-demand media and buffer manufacturing system transforming scale bioproduction. SAN DIEGO - (BUSINESS WIRE) - #bioprocess - Nucleus Biologics launched the Krakatoa(R) K500, a pod-based, on-demand manufacturing system that produces 35 - 500L of media and buffers at point of use. Click here to view original post

PR Newswire
Jan 9th, 2025
Nucleus Biologics Becomes First Custom Cell Culture Media Company To Achieve Excipact Certification For The Manufacture Of Excipient Gmp Quality Cell Culture Media, Supplements, And Buffers

SAN DIEGO, Jan. 9, 2025 /PRNewswire/ - Nucleus Biologics, a leader in precision cell culture media development, is proud to announce that it has achieved an industry-leading quality milestone. It has received EXCiPACT certification for Pharmaceutical Excipients and Pharmaceutical Auxiliary Materials (PAMs) and ISO 9001 certification from SGS. This Excipient GMP certification will better support the cell culture media, buffers, reagents, and supplements needs for our cell and gene therapy customers. This certification, in addition to our ISO 13485 certification, underscores Nucleus Biologics' commitment to delivering the highest quality products that meet the most stringent safety, consistency, and compliance requirements of the biopharmaceutical industry.EXCiPACT is an internationally recognized certification standard specifically designed for excipient manufacturers. It ensures that facilities adhere to the highest standards of Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP)